Systemic Lupus Erythematosus Market Outlook 2031
The global systemic lupus erythematosus market size was valued at USD 202.09 Billion in 2022 and is projected to reach USD 313.51 Billion by 2031, expanding at a CAGR of 5% during the forecast period, 2023–2031. The growth of the market is attributed to the arrival of key pipeline agents with improved efficacy compared to existing therapies.
To keep the body healthy, the immune system typically fights off harmful diseases and germs. When the immune system misidentifies the body as something alien, it develops an autoimmune disease. Although the word lupus has been used to describe a variety of immunological disorders with comparable clinical and laboratory characteristics, systemic lupus erythematosus (SLE) is the most prevalent form of lupus.
When people mention lupus, they frequently mean SLE. SLE is an autoimmune disease in which the immune system targets the body's own tissues, resulting in extensive inflammation and tissue destruction in the organs affected. Joints, skin, brain, lungs, kidneys, and blood vessels can all be affected.
Lupus has no cure, although it can be managed with medical intervention and lifestyle modifications. SLE is a chronic condition characterized by periods of increasing symptoms followed by periods of moderate symptoms. With therapy, most persons with SLE can live a normal life. Symptoms for SLE can vary and can change over time.
Common symptoms for SLE includes severe fatigue, joint pain, joint swelling, headaches, a rash on the cheeks and nose called a butterfly rash, hair loss, anemia, blood-clotting problems, and fingers turning white or blue and tingling when cold, which is known as Raynaud’s phenomenon.
Other symptoms vary depending on which region of the body the disease is targeting, such as the digestive tract, heart, or skin. SLE symptoms overlap with variety of different diseases, making diagnosis tricky. The actual cause of SLE is unknown, however it has been linked to a number of conditions. Genetics, the environment, and sex & hormones are some of the conditions.
Some of the environmental triggers includes UV radiation, some medicines, viruses, physical or emotional stress, and trauma. Women are more affected by SLE than males. Symptoms may be worsened for women during pregnancy and throughout their menstrual periods. Both of these findings have prompted some medical experts to conclude that estrogen, a female hormone, may have a role in the development of SLE.
There is no one test that can diagnose SLE, however blood tests including antibody testing and a complete blood count, urinalysis, and a chest X-ray can assist doctor to make an informed diagnosis. The objective of SLE therapy is to ease the symptoms. Treatment depends on the severity of your symptoms and which regions of your body are affected by SLE.
Anti-inflammatory medications for joint pain and stiffness, such as these online options, steroid creams for rashes, corticosteroids to reduce the immune response, antimalarial drugs for skin and joint problems, disease modifying drugs, or targeted immune system agents for more severe cases are all possible treatments for SLE.
To decrease the chances of triggering symptoms, doctor may prescribe eating or avoiding specific foods and reducing stress. Because steroids might thin bones, the patient may need to be screened for osteoporosis. Preventive treatment, such as safe immunizations for those with autoimmune disorders and cardiac tests, may also be recommended by doctor.
Systemic Lupus Erythematosus Market Trends, Drivers, Restraints, and Opportunities
- Rising incidence of systemic lupus erythematosus, which in turn is increasing the demand for effective treatments options is projected to boost the market growth during the forecast period.
- Introduction of key pipeline agents in the market and various new drug approvals is anticipated to fuel the market growth in the coming years.
- Growing geriatric population is expected to drive the market growth during the forecast period.
- Stringent regulations for drug approval in various markets presents as key challenge that can restrict the market growth during the forecast period.
- High price of drugs for treatment of SLE is anticipated to hamper the market growth during the forecast period.
- Increased R&D investment for development of novel SLE drugs with better efficacy and technological advancements are projected to offer immense opportunities for the market players.
Scope of Systemic Lupus Erythematosus Market Report
The report on the global systemic lupus erythematosus market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Systemic Lupus Erythematosus Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics), Route of Administration (Oral, Intravenous, and Subcutaneous)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AstraZeneca; Merck & Co., Inc.; Bristol-Myers Squibb Company; Anthera Pharmaceuticals, Inc.; ImmuPharma PLC; and Aurinia Pharmaceuticals, Inc.
|
Systemic Lupus Erythematosus Market Segment Insights
Drug Class Segment Analysis
Based on drug class, the systemic lupus erythematosus market is segmented into NSAIDs, corticosteroids, antimalarials, immunosuppressants, and biologics. The immunosuppressants segment is expected to account for a key share of the market during the forecast period owing to increasing adoption of methotrexate worldwide, due to its availability at low cost.
On the other hand, the biologics segment is anticipated to expand at a rapid pace during the forecast period due to introduction of new biologics with improved efficacy. Benlysta, the first on-label biologic for the treatment of SLE, has received physician approval for mild to moderate SLE.
For the severe form, however, its efficacy and safety are currently being evaluated. Other biologic agents, such as rituximab, are also utilized as an off-label therapy for systemic lupus erythematosus since, unlike corticosteroids and immunosuppressants, they have no adverse effects.
Route of Administration Segment Analysis
Based on route of administration, the systemic lupus erythematosus market is segmented into oral, intravenous, and subcutaneous. The oral segment is expected to constitute a key share of the market during the forecast period owing to its ease of administration and being the mainstream treatment for SLE.
On the other hand, the subcutaneous segment is anticipated to expand at a rapid pace during the forecast period due to approval of a subcutaneous formulation of Benlysta and rituximab in several countries, including the US and several European countries.
Regional Outlook
On the basis of regions, the systemic lupus erythematosus market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to increasing incidence of SLE, improved healthcare infrastructure and presence of specialty drugs.
On the other hand, Europe is expected to exhibit a rapid growth rate in the coming years due to better presence of coverage policies, increased adoption of belimumab as it is available in both formulations. In addition to this, UK, Germany, Spain, Italy, and France were the first countries in the European Union to approve Benlysta as an add-on medication for the treatment of active SLE.
Segments
The global systemic lupus erythematosus market has been segmented on the basis of
Drug Classes
- NSAIDs
- Corticosteroids
- Antimalarials
- Immunosuppressants
- Biologics
Route of Administration
- Oral
- Intravenous
- Subcutaneous
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- AstraZeneca
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Anthera Pharmaceuticals, Inc.
- ImmuPharma PLC
- Aurinia Pharmaceuticals, Inc.
Competitive Landscape
Key players competing in the systemic lupus erythematosus market are GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AstraZeneca; Merck & Co., Inc.; Bristol-Myers Squibb Company; Anthera Pharmaceuticals, Inc.; ImmuPharma PLC; and Aurinia Pharmaceuticals, Inc.
Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For instance, Clinical studies using Benlysta and rituximab are being conducted by GlaxoSmithKline and Roche to assess their combined effectiveness in treating severe symptoms of SLE.
New players such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca are expected to introduce promising treatments such as Lupuzor, Voclosporin, and anifrolumab, the coming years.
Request For Customization
Enquiry Before Buying
Speak With Analyst
